Filing Flows

Filing Flows › Halozyme Therapeutics (HALO) › Next earnings date

Halozyme Therapeutics (HALO) earnings: beat the estimate

Halozyme Therapeutics (HALO) reported on Nov 5, 2026 and beat the EPS estimate: $2.39 against $2.36 (+1.5%). Revenue was $493M for Q3 2026, +39% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+1.5% vs estimate
Beat rate80%

The last report

Halozyme Therapeutics reported revenue of $493M for the third quarter 2026 (+39% Y/Y), net earnings $247M: Royalties $341M, Product sales, net $137M, Revenues under collaborative agreements $14.6M. How it makes money → · Every quarter →

Halozyme Therapeutics: EPS against the estimate, last 5 reportsHalozyme Therapeutics: EPS against the estimate, last 5 reportsEstimateReported$1.63$1.72Nov 25$2.20−$0.24Feb 26$1.52$1.60May 26$1.82$2.28Aug 26$2.36$2.39Nov 26
Latest (Nov 26): Estimate $2.36, Reported $2.39.
HALO: the stock's move on each reportHALO: the stock's move on each reportAug 6, 2026+23.4%May 11, 2026+10.6%Feb 17, 2026-7.8%Nov 3, 2025+4.4%

Halozyme Therapeutics' latest quarter

Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.

Questions

Did Halozyme Therapeutics beat earnings?

Halozyme Therapeutics (HALO) reported on Nov 5, 2026 and beat the EPS estimate: $2.39 against $2.36 (+1.5%).

When does HALO report earnings?

The next date is not set yet.

Does Halozyme Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.